NV1020

AXP000075.1 · Oncolytic virus

Platform
HSV-1/HSV-2 recombinant (R7020 backbone)
Originator
University of Chicago (Bernard Roizman)
Sponsor
MediGene

Names

NameTypeSource
NV1020preferred name, codecurator, ncit
R7020former codencit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
R7020 (HSV-1 F background with HSV-2 sequences)
Replication
conditionally replicating
Modifications
one copy each of RL1 (gamma34.5), ICP0 and ICP4 deleted; UL56 deleted; internal repeat replaced by an HSV-2 US fragment; thymidine kinase placed under the ICP4 promoter
Route
intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C2623

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00149396Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the LiverCompletedPhase 1/22004-072008-1032Colorectal Cancer; Liver Neoplasms
NCT00012155Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the LiverCompletedPhase 12000-102002-11Colorectal Cancer; Metastatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 21895536Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.Human gene therapy2012cited by trial NCT00149396
PMID 20486770Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.Human gene therapy2010name in title: NV1020
PMID 19018254A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.Molecular therapy : the journal of the American Society of Gene Therapy2009name in abstract: NV1020
PMID 17107303Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.Human gene therapy2006name in title: NV1020

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 29896663Oncolytic Virotherapy by HSV.Advances in experimental medicine and biology2018name in abstract: NV1020
PMID 30563466Oncolytic herpes simplex virus and immunotherapy.BMC immunology2018name in abstract: NV1020
PMID 26132411Evidence for the Use of Multiple Mechanisms by Herpes Simplex Virus-1 R7020 to Inhibit Intimal Hyperplasia.PloS one2015name in title: R7020
PMID 21567107Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines.Oncology reports2011name in abstract: NV1020
PMID 19526622Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts.The British journal of surgery2009name in abstract: NV1020
PMID 18518998Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Virology journal2008name in title: NV1020
PMID 18549346Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy.Expert opinion on investigational drugs2008name in title: NV1020
PMID 17536976Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.Human gene therapy2007name in title: NV1020
PMID 16475242Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.The journal of gene medicine2006name in abstract: NV1020
PMID 16574492Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein.Molecular therapy : the journal of the American Society of Gene Therapy2006name in abstract: NV1020
PMID 16675589Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in abstract: NV1020
PMID 17117895Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells.Human gene therapy2006name in title: NV1020
PMID 15665822Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses.Cancer gene therapy2005name in abstract: NV1020
PMID 15696053Modulation of vascular remodeling induced by a brief intraluminal exposure to the recombinant R7020 strain of Herpes simplex-1.Journal of vascular surgery2005name in title: R7020
PMID 15735042Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.Cancer research2005name in abstract: NV1020
PMID 16121703Technology evaluation: NV-1020, MediGene.Current opinion in molecular therapeutics2005name in title: NV1020
PMID 15185293Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy.Hepatology (Baltimore, Md.)2004name in abstract: NV1020
PMID 11850725The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.Gene therapy2002name in title: R7020
PMID 12091817Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model.The Journal of thoracic and cardiovascular surgery2002name in title: NV1020
PMID 12218591Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses.Journal of pediatric hematology/oncology2002name in abstract: NV1020
PMID 12242723Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.The Prostate2002name in abstract: NV1020
PMID 12386832Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.Cancer gene therapy2002name in title: NV1020
PMID 12522436Oncolytic herpes simplex virus vectors for cancer virotherapy.Cancer gene therapy2002name in abstract: NV1020
PMID 11344122Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology2001name in title: NV1020
PMID 11442249Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.Journal of the American College of Surgeons2001name in abstract: NV1020
PMID 11119418Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy.Human gene therapy2000name in abstract: NV1020
PMID 11307092Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2000name in abstract: NV1020
PMID 2165104In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus).The Journal of infectious diseases1990name in title: R7020
PMID 2842408In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents.The Journal of infectious diseases1988name in title: R7020
Unconfirmed matches (3)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 25119379Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.Gene therapy2014name in abstract: R7020
PMID 10232586Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.Cancer research1999name in abstract: R7020
PMID 1780614Genetically engineered attenuated herpes simplex viruses.Reviews of infectious diseases1991name in abstract: R7020

NIH grants

No confirmed grants yet.

Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
R01CA083066IMAGING TRANSGENE EXPRESSION IN GENE THERAPY PROTOCOLSSLOAN-KETTERING INST CAN RESEARCHBLASBERG, RONALD G2002–2004name in abstract: R7020

Notes

Originally R7020, built as a live attenuated HSV vaccine candidate, later developed as an oncolytic for colorectal liver metastases by NeuroVir and MediGene (phase I/II by hepatic arterial infusion). Discontinued; the asset later passed to Catherex, acquired by Amgen in 2015 (deal not re-verified here).

How to cite

NV1020 (AXP000075.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000075.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.